Management of Lower Urinary Tract Symptoms in Hypertensive Patients

Medication Options

For patients with lower urinary tract symptoms (LUTS) already on tamsulosin who also have hypertension, adding a 5-alpha reductase inhibitor (5-ARI) like finasteride or dutasteride is the most appropriate option, especially if the patient has prostatic enlargement, as recommended by the American Urological Association 1, 2
5-ARIs (finasteride or dutasteride) are appropriate additions to tamsulosin for patients with demonstrable prostatic enlargement, according to the European Association of Urology 3, 2
These medications reduce prostate size by 18-28%, improve symptoms by 15-30%, and increase maximum flow rate by 1.5-2.0 ml/s, as reported by the European Urology journal 4
5-ARIs reduce the risk of acute urinary retention by 57-68% and need for surgery by 55-64% at 4 years, as stated by the European Urology journal 4
Tadalafil 5mg daily is the only PDE5 inhibitor licensed for LUTS treatment, as approved by the European Medicines Agency 4
Combination of PDE5 inhibitors with alpha-blockers can significantly improve IPSS score (-1.8), erectile function (+3.6), and maximum flow rate (+1.5 ml/s) compared to alpha-blocker monotherapy, as reported by the European Urology journal 4

Tamsulosin has a lower probability of orthostatic hypotension compared to other alpha-blockers but higher probability of ejaculatory dysfunction, as noted by the American Urological Association 3, 2
Alpha-blockers used for LUTS should not be assumed to provide optimal management of hypertension; separate management of hypertension may be required, as recommended by the International Society of Hypertension 3, 2
The International Society of Hypertension recommends following the ISH 2020 guidelines for hypertension management 5

Assess prostate size (via DRE and/or PSA) and add a 5-ARI (finasteride or dutasteride) if prostate is enlarged (>40ml), as recommended by the European Association of Urology 1, 2, 4
Evaluate predominant symptom type and consider combination therapy for mixed storage and voiding symptoms, as suggested by the American Urological Association 1, 4

5-ARIs: Sexual dysfunction (reduced libido, erectile dysfunction, ejaculation disorders), effect on PSA (reduces by approximately 50%), as reported by the European Urology journal 4
PDE5 inhibitors: Flushing, gastroesophageal reflux, headache, dyspepsia, back pain, nasal congestion, as listed by the European Urology journal 4

Assess treatment success of 5-ARIs after at least 3 months, as recommended by the American Urological Association 1
Re-evaluate LUTS symptoms and potential side effects at follow-up visits, as suggested by the European Association of Urology 1, 4

The American Urological Association guidelines support combination therapy for patients with persistent symptoms despite alpha-blocker monotherapy, as alpha-blockers provide rapid symptom relief by relaxing prostatic smooth muscle but do not affect disease progression 6, 7
5-Alpha reductase inhibitors address the underlying pathophysiology by reducing prostate size and preventing disease progression, and are particularly beneficial for patients with larger prostates and higher risk of disease progression 7

Alpha-blockers used for LUTS should not be assumed to provide optimal management of hypertension; separate management of hypertension may be required, and tamsulosin has a lower probability of orthostatic hypotension compared to other alpha-blockers, which is beneficial given the patient's cardiovascular comorbidities 8

Consider urodynamic studies if symptoms persist despite optimized medical therapy, and evaluate for potential urinary retention with post-void residual measurement, particularly important in a patient with multiple comorbidities 9

Tamsulosin 0.4 mg once daily is recommended as the first‑line alpha‑blocker for patients who have both BPH and established cardiovascular disease or hypertension because it is a selective α1A‑adrenergic antagonist that produces minimal blood‑pressure reductions and does not require dose titration, thereby avoiding interactions with existing antihypertensive therapy. (American College of Cardiology) 10
Tamsulosin does not require dose escalation; this eliminates a period of cardiovascular instability that can occur with titrated agents. (American College of Cardiology) 11

Alfuzosin can be used as an alternative to tamsulosin; it provides comparable efficacy for BPH symptoms and also does not need dose titration, although it is associated with slightly higher rates of dizziness than tamsulosin. (American College of Cardiology) 11

The 2017 ACC/AHA Hypertension Guidelines state that α1‑blockers may be considered only as second‑line agents for patients who have both hypertension and BPH; they should not be used as primary antihypertensive therapy. (ACC/AHA) 10
Patients should continue their existing antihypertensive regimen unchanged when an alpha‑blocker is added for BPH. (American College of Cardiology) 10
An alpha‑blocker prescribed for BPH should not be substituted for any of the patient’s current blood‑pressure medications. (American College of Cardiology) 10
Clinicians must not assume that treating BPH with an alpha‑blocker also provides adequate control of hypertension; the two conditions require independent management. (American College of Cardiology) 10